Delivering gene therapy directly to the brain for AADC deficiency
PTC Therapeutics’ gene therapy delivered directly to the brain is yielding life-changing results in children with AADC deficiency.
By
PTC Therapeutics’ gene therapy delivered directly to the brain is yielding life-changing results in children with AADC deficiency.
ByA new paradigm for HIV treatment is on the horizon as FDA gives nod for startup to begin trials of…
ByThe Alliance for Regenerative Medicine’s report reveals the data behind a “year of firsts and records” for the sector.
ByNetherlands-based gene therapy developer uniQure has announced the results of a comprehensive investigation into the case of hepatocellular carcinoma (HCC)…
ByAt the 15th International Virtual Conference on Alzheimer’s disease (AD) and Parkinson’s disease (PD) 2021, a clinical-stage biotech company based…
ByGlaxoSmithKline (GSK) will expand its presence at the UK Cell and Gene Therapy (CGT) Catapult’s Stevenage facility to carry out…
On March 4, Galapagos announced pooled interim results from its ongoing MANTA and MANTA-RAy testicular safety studies for Jyseleca (filgotinib)…
With new SARS-CoV-2 variant strains appearing, the global race to control the COVID-19 pandemic through immunization is on. Europe remains…
Thank you for subscribing to Clinical Trials Arena